Literature DB >> 10676700

Polymeric-based perivascular delivery of a nitric oxide donor inhibits intimal thickening after balloon denudation arterial injury: role of nuclear factor-kappaB.

S Kaul1, B Cercek, J Rengstrom, X P Xu, M D Molloy, P Dimayuga, A K Parikh, M C Fishbein, J Nilsson, T B Rajavashisth, P K Shah.   

Abstract

OBJECTIVES: To examine the effect of a polymeric-based periadventitial delivery of a nitric oxide (NO)-releasing diazeniumdiolate, spermine/NO (SPER/NO), on balloon injury-induced neointimal hyperplasia in rat ileofemoral arteries.
BACKGROUND: Reduced local bioavailability and adverse side effects limit systemic administration of NO to modulate vascular response to injury.
METHODS: A polylactic-polyglycolic acid polymeric matrix containing 2.5% SPER/NO (w/w) was applied around the injured arteries. Quantitative histomorphometry was performed at day 14, proliferating cell nuclear antigen (PCNA) immunohistochemistry at day 3 to assess effects on smooth muscle proliferation and electrophoretic mobility shift assay to evaluate effects on transcription factor, nuclear factor-kappaB (NF-kappaB).
RESULTS: Treatment with SPER/NO reduced the intimal area (0.011 +/- 0.009 vs. 0.035 +/- 0.006 mm2 control, p < 0.01) and the intima to media ratio (0.089 +/- 0.062 vs. 0.330 +/- 0.057 control, p < 0.005). Spermine/nitric oxide produced a profound inhibition of PCNA-positive cells (>75%, p < 0.005) and significantly suppressed the injury-induced activation of NF-kappaB. Vascular cyclic guanosine monophosphate (cGMP) levels were elevated after treatment with the SPER/NO (0.28 +/- 0.03 vs. 0.17 +/- 0.02 pmol/mg tissue control, p < 0.01). The inhibitory effects on neointimal proliferation were localized to the site of application of SPER/NO and were not associated with any changes in platelet aggregation or bleeding time. Neither SPER nor polymer alone had any significant effects on any of the variables examined.
CONCLUSIONS: Polymeric-based perivascular delivery of a NO donor produces a marked localized inhibition of neointimal proliferation in balloon-injured arteries. This phenomenon is associated with suppression of NF-kappaB activation and elevation of the vascular cGMP at the site of injury.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10676700     DOI: 10.1016/s0735-1097(99)00543-4

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  19 in total

Review 1.  Recent developments in nitric oxide donor drugs.

Authors:  M R Miller; I L Megson
Journal:  Br J Pharmacol       Date:  2007-04-02       Impact factor: 8.739

2.  Insights into the effect of nitric oxide and its metabolites nitrite and nitrate at inhibiting neointimal hyperplasia.

Authors:  Ashley K Vavra; George E Havelka; Janet Martinez; Vanessa R Lee; Bo Fu; Qun Jiang; Larry K Keefer; Melina R Kibbe
Journal:  Nitric Oxide       Date:  2011-04-30       Impact factor: 4.427

Review 3.  Nitric oxide: what's new to NO?

Authors:  Kedar Ghimire; Helene M Altmann; Adam C Straub; Jeffrey S Isenberg
Journal:  Am J Physiol Cell Physiol       Date:  2016-12-14       Impact factor: 4.249

4.  Nitric oxide increases lysine 48-linked ubiquitination following arterial injury.

Authors:  Chris S Oustwani; Nick D Tsihlis; Ashley K Vavra; Qun Jiang; Janet Martinez; Melina R Kibbe
Journal:  J Surg Res       Date:  2011-06-15       Impact factor: 2.192

5.  Polymer-Based Nitric Oxide Therapies: Recent Insights for Biomedical Applications.

Authors:  Michele C Jen; María C Serrano; Robert van Lith; Guillermo A Ameer
Journal:  Adv Funct Mater       Date:  2012-01-25       Impact factor: 18.808

6.  Poly(diol-co-citrate)s as novel elastomeric perivascular wraps for the reduction of neointimal hyperplasia.

Authors:  M Concepcion Serrano; Ashley K Vavra; Michele Jen; Melissa E Hogg; Jozef Murar; Janet Martinez; Larry K Keefer; Guillermo A Ameer; Melina R Kibbe
Journal:  Macromol Biosci       Date:  2011-02-21       Impact factor: 4.979

7.  Role of metabolic environment on nitric oxide mediated inhibition of neointimal hyperplasia in type 1 and type 2 diabetes.

Authors:  Monica P Rodriguez; Zachary M Emond; Zheng Wang; Janet Martinez; Qun Jiang; Melina R Kibbe
Journal:  Nitric Oxide       Date:  2013-12-12       Impact factor: 4.427

8.  Insulin enhances the effect of nitric oxide at inhibiting neointimal hyperplasia in a rat model of type 1 diabetes.

Authors:  Vinit N Varu; Sadie S Ahanchi; Melissa E Hogg; Hussein A Bhikhapurwala; Amy Chen; Daniel A Popowich; Ashley K Vavra; Janet Martinez; Qun Jiang; Joseph E Saavedra; Joseph A Hrabie; Larry K Keefer; Melina R Kibbe
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-06-18       Impact factor: 4.733

9.  Nitric oxide and nanotechnology: a novel approach to inhibit neointimal hyperplasia.

Authors:  Muneera R Kapadia; Lesley W Chow; Nick D Tsihlis; Sadaf S Ahanchi; Jason W Eng; Jozef Murar; Janet Martinez; Daniel A Popowich; Qun Jiang; Joseph A Hrabie; Joseph E Saavedra; Larry K Keefer; James F Hulvat; Samuel I Stupp; Melina R Kibbe
Journal:  J Vasc Surg       Date:  2008-01       Impact factor: 4.268

10.  In vitro and in vivo study of sustained nitric oxide release coating using diazeniumdiolate-oped poly(vinyl chloride) matrix with poly(lactide-co-glycolide) additive.

Authors:  Hitesh Handa; Elizabeth J Brisbois; Terry C Major; Lahdan Refahiyat; Kagya A Amoako; Gail M Annich; Robert H Bartlett; Mark E Meyerhoff
Journal:  J Mater Chem B       Date:  2013-08-07       Impact factor: 6.331

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.